Mayo Clinic CEO announces retirement after nearly a decade at the helm

By Catherine Sturman
President and CEO of Mayo Clinic, Dr John Noseworthy has announced his plans to retire at the end of 2018 after nine years leading the research group...

President and CEO of Mayo Clinic, Dr John Noseworthy has announced his plans to retire at the end of 2018 after nine years leading the research group’s operations and 28 years at the Clinic.

The clinic’s reputation has soared under Dr Noseworthy’s leadership, where it has seen one of the its strongest years with regards to quality and safety, research advancements and clinical practice. It has also completed its $3.76bn, eight-year philanthropic campaign.

“2017 was an extraordinary year for Mayo Clinic, and I look forward to working with our leadership team throughout 2018 to continue to strengthen Mayo Clinic and advance our humanitarian mission,” said Dr Noseworthy.

Mayo’s 2017 annual report, highlights that it has gained over $700mn in income, with a 49% increase in net income from 2016. The clinic has also undergone a significant recruitment drive.

See also

“Dr. Noseworthy’s inspirational and compassionate leadership has guided the organisation from a group of separate clinics and hospitals to a single integrated organisation focused on serving our patients,” added Jeff Bolton, Vice President, Administration, Mayo Clinic.

Samuel Di Piazza, Chair, Mayo Clinic Board of Trustees commented, “During his tenure as CEO, Dr. Noseworthy led Mayo Clinic to focus on key priorities, significantly increase its external visibility and achieve designation as the No. 1 hospital in the nation by U.S. News & World Report in 2016 and 2017.

“Mayo Clinic has consistently advanced its strategic direction under Dr. Noseworthy’s leadership and is well-positioned for continued success in 2018.”

Its new CEO will be announced in August once identified and transition plans are put in place.

Share

Featured Articles

Grifols & Orange Business Launch Egypt Plasma Project

Grifols & Orange Business Complete landmark phase of Data Centre for Plasma Derivatives Facility, designed to boost healthcare in Egypt

Healthcare business roundup: Eli Lilly, Novo Nordisk, Aspen

Eli Lilly's experimental cardiovascular drug ‘promising’; Aspen Pharmacare to manufacture mpox vaccines; Novo Nordisk says Ozempic shortage ‘worsening’

Global Health Funding 'Facing Post-Pandemic Challenges'

IHME report highlights shifting priorities and economic pressures affecting global health financing, despite increase in funding since pre-COVID levels

The Merck Group: Pharma's History & Innovation in India

Medical Devices & Pharma

How CVS Health is Rising to the Omnichannel Challenge

Procurement & Supply Chain

Kinaxis: Pharma Seeing Euro-wide Supply Chain Challenges

Procurement & Supply Chain